scispace - formally typeset
K

Ken Watanabe

Researcher at University of Tokyo

Publications -  13
Citations -  296

Ken Watanabe is an academic researcher from University of Tokyo. The author has contributed to research in topics: Vitrectomy & Epiretinal membrane. The author has an hindex of 6, co-authored 13 publications receiving 213 citations.

Papers
More filters
Journal ArticleDOI

Outer Retinal Morphology and Visual Function in Patients With Idiopathic Epiretinal Membrane

TL;DR: At an early stage of an ERM, only the photoreceptor structures are significantly associated with the BCVA, and the appearance of the COST line was most highly associated.
Journal ArticleDOI

Highly reflective foveal region in optical coherence tomography in eyes with vitreomacular traction or epiretinal membrane.

TL;DR: The highly reflective region is a characteristic sign observed in the OCT images of eyes with VMT and ERM, and it has been termed the cotton ball sign after its appearance and may be a predictor of visual impairment.
Journal ArticleDOI

Internal Limiting Membrane Peeling to Prevent Post-vitrectomy Epiretinal Membrane Development in Retinal Detachment.

TL;DR: ILM peeling without ICG staining during the initial vitrectomy for RRDs may prevent postoperative ERM formation with favorable visual outcomes, and there was no significant difference in the final BCVA between subgroups with and without ILMpeeling.
Journal ArticleDOI

Clinical course of focal choroidal excavation in Vogt–Koyanagi–Harada disease

TL;DR: F focal choroidal excavation in a case of Vogt–Koyanagi–Harada (VKH) disease is described and findings suggest that the natively existent FCE could be affected by pathophysiological changes of VKH as well as other chorioretinal conditions.
Journal ArticleDOI

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement

TL;DR: Conversion to IVA was effective in patients with AMD resistant to ranibizumab, showing rapid morphologic improvement and the logMAR visual acuity was raised significantly within 12 months, and the clinical course ofVisual acuity improvement may differ according to the AMD subtypes.